Robert Hershberg

Dr. Hershberg has worked for over 30 years in downstream processing of biopharmaceuticals specializing in process development, formulation and implementation of processes into manufacturing. At Hoffman-L Roche, he managed a group responsible for production, isolation, purification, and formulation of natural and recombinant alpha-interferon. At Genentech, he managed an integrated development team involved in large-scale recovery operations utilizing both bacterial and mammalian cell culture technologies. He worked on processes and/or formulations for the following products: Roferon™, Actimmune™, Pulmozyme™, Nutropin AQ™, Kogenate™, Herceptin™, and Hepatitis B vaccine. In addition, at Amgen, he led a group that contributed to the development of processes for commercial manufacture of Enbrel™ and Denosumab™.